Laboratorios Farmaceuticos ROVI SA
OTC:LABFF

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Watchlist
Price: 90.61 USD Market Closed
Market Cap: 4.6B USD
Section:
 

Relative Value

The Relative Value of one LABFF stock under the Base Case scenario is hidden USD. Compared to the current market price of 90.61 USD, Laboratorios Farmaceuticos ROVI SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LABFF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

4.4
P/S
P/S
Price to Sales
4.4
vs History
15
vs Industry
43
Median 3Y
3.6
Median 5Y
3.7
Industry
2.6
Forward
4.3
More Details
26.4
P/E
P/E
Price to Earnings
26.4
vs History
6
vs Industry
35
Median 3Y
18.8
Median 5Y
19.3
Industry
21.7
Forward
25.3
More Details
18.1
P/OCF
P/OCF
Price to OCF
18.1
vs History
63
vs Industry
20
Median 3Y
20.4
Median 5Y
20.3
Industry
16.7
More Details
31.8
P/FCFE
P/FCFE
Price to FCFE
31.8
vs History
41
vs Industry
20
Median 3Y
31.5
Median 5Y
30.5
Industry
23.1
More Details
5.7
P/B
P/B
Price to Book Value
5.7
vs History
52
vs Industry
15
Median 3Y
5.4
Median 5Y
5.8
Industry
2.2
More Details
4.5
EV/S
EV/S
Enterprise Value to Sales
4.5
vs History
15
vs Industry
40
Median 3Y
3.7
Median 5Y
3.7
Industry
2.9
Forward
4.4
More Details
7
EV/GP
EV/GP
Enterprise Value to Gross Profit
7
vs History
23
vs Industry
44
Median 3Y
5.9
Median 5Y
6
Industry
5.5
More Details
17.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.1
vs History
15
vs Industry
35
Median 3Y
12.9
Median 5Y
13.4
Industry
13.2
Forward
17.3
More Details
20.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
20.3
vs History
11
vs Industry
37
Median 3Y
14.7
Median 5Y
15
Industry
16.8
Forward
20.4
More Details
18.4
EV/OCF
EV/OCF
Enterprise Value to OCF
18.4
vs History
61
vs Industry
20
Median 3Y
20.8
Median 5Y
20.1
Industry
15.9
More Details
29.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
29.6
vs History
58
vs Industry
11
Median 3Y
38.8
Median 5Y
34.7
Industry
19.2
More Details
4.2
EV/IC
EV/IC
Enterprise Value to IC
4.2
vs History
58
vs Industry
20
Median 3Y
4.1
Median 5Y
4.6
Industry
1.9
More Details

Multiples Across Competitors

LABFF Competitors Multiples
Laboratorios Farmaceuticos ROVI SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
3.2B USD 4.4 26.4 17.1 20.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.1 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
211.9B GBP 4.9 30.4 108.8 159.3
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
261.3B USD 4.1 13.7 9.8 11.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
141.5B USD 2.3 14.4 7.4 10.1
P/E Multiple
Earnings Growth PEG
ES
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Average P/E: 24.5
26.4
16%
1.6
US
Eli Lilly and Co
NYSE:LLY
55.1
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.4
38%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
4%
3.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.4
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Average EV/EBITDA: 400.7
17.1
15%
1.1
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
2%
5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Average EV/EBIT: 1 712.3
20.3
15%
1.4
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3

See Also

Summary
LABFF intrinsic value, competitors valuation, and company profile.
DCF Valuation
LABFF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LABFF stock valuation using valuation multiples.
Wall Street Estimates
LABFF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LABFF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.